{"title":"BNT162b2 作为 ChAdOx1 初级系列治疗后的第一支增强剂在泰国老年体弱人群中的免疫原性","authors":"","doi":"10.1016/j.jnha.2024.100315","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Impact of frailty towards immunogenicity and reactogenicity of BNT162b2 boosters administered via intramuscular or intradermal routes in a Thai geriatric population</p></div><div><h3>Design</h3><p>Prospective, randomized, open-labeled.</p></div><div><h3>Setting</h3><p>Siriraj Hospital, Thailand.</p></div><div><h3>Participants</h3><p>Geriatric adults aged ≥65 years.</p></div><div><h3>Intervention</h3><p>10 μg intradermal or 30 μg intramuscular BNT162b2 (Pfizer-BioNTech).</p></div><div><h3>Measurements</h3><p>Anti-SARS-CoV-2 receptor binding domain IgG, neutralizing antibodies (NAb), and interferon-gamma producing cells against Wuhan and Omicron BA.4/5. Analyses were stratified based on participants’ Clinical Frailty Scale.</p></div><div><h3>Results</h3><p>A total of 139 participants were included in the analysis. Two-four weeks post-booster administration, NAb titers against Wuhan but not Omicron BA.4/5 were significantly lower among frail participants than non-frail participants who received intramuscular administration. Spike-specific T cell responses were similar for frail and non-frail participants, regardless of administration route. Frail participants who received intradermal BNT162b2 had fewer local adverse events (AEs), but higher systemic AEs than non-frail participants.</p></div><div><h3>Conclusion</h3><p>Similar immune responses across vaccine routes warrants further evaluation of intradermal BNT162b2 in frail geriatric populations. Frail participants may be more sensitive to reporting systemic AEs.</p></div><div><h3>Registration of clinical trials</h3><p>The parent study was registered under the Thai Clinical Trials Registry (TCTR20220112002).</p></div>","PeriodicalId":54778,"journal":{"name":"Journal of Nutrition Health & Aging","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1279770724004020/pdfft?md5=608a02641f6454280eea7645977239b6&pid=1-s2.0-S1279770724004020-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty\",\"authors\":\"\",\"doi\":\"10.1016/j.jnha.2024.100315\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Impact of frailty towards immunogenicity and reactogenicity of BNT162b2 boosters administered via intramuscular or intradermal routes in a Thai geriatric population</p></div><div><h3>Design</h3><p>Prospective, randomized, open-labeled.</p></div><div><h3>Setting</h3><p>Siriraj Hospital, Thailand.</p></div><div><h3>Participants</h3><p>Geriatric adults aged ≥65 years.</p></div><div><h3>Intervention</h3><p>10 μg intradermal or 30 μg intramuscular BNT162b2 (Pfizer-BioNTech).</p></div><div><h3>Measurements</h3><p>Anti-SARS-CoV-2 receptor binding domain IgG, neutralizing antibodies (NAb), and interferon-gamma producing cells against Wuhan and Omicron BA.4/5. Analyses were stratified based on participants’ Clinical Frailty Scale.</p></div><div><h3>Results</h3><p>A total of 139 participants were included in the analysis. Two-four weeks post-booster administration, NAb titers against Wuhan but not Omicron BA.4/5 were significantly lower among frail participants than non-frail participants who received intramuscular administration. Spike-specific T cell responses were similar for frail and non-frail participants, regardless of administration route. Frail participants who received intradermal BNT162b2 had fewer local adverse events (AEs), but higher systemic AEs than non-frail participants.</p></div><div><h3>Conclusion</h3><p>Similar immune responses across vaccine routes warrants further evaluation of intradermal BNT162b2 in frail geriatric populations. Frail participants may be more sensitive to reporting systemic AEs.</p></div><div><h3>Registration of clinical trials</h3><p>The parent study was registered under the Thai Clinical Trials Registry (TCTR20220112002).</p></div>\",\"PeriodicalId\":54778,\"journal\":{\"name\":\"Journal of Nutrition Health & Aging\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1279770724004020/pdfft?md5=608a02641f6454280eea7645977239b6&pid=1-s2.0-S1279770724004020-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nutrition Health & Aging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1279770724004020\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nutrition Health & Aging","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1279770724004020","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty
Objectives
Impact of frailty towards immunogenicity and reactogenicity of BNT162b2 boosters administered via intramuscular or intradermal routes in a Thai geriatric population
Design
Prospective, randomized, open-labeled.
Setting
Siriraj Hospital, Thailand.
Participants
Geriatric adults aged ≥65 years.
Intervention
10 μg intradermal or 30 μg intramuscular BNT162b2 (Pfizer-BioNTech).
Measurements
Anti-SARS-CoV-2 receptor binding domain IgG, neutralizing antibodies (NAb), and interferon-gamma producing cells against Wuhan and Omicron BA.4/5. Analyses were stratified based on participants’ Clinical Frailty Scale.
Results
A total of 139 participants were included in the analysis. Two-four weeks post-booster administration, NAb titers against Wuhan but not Omicron BA.4/5 were significantly lower among frail participants than non-frail participants who received intramuscular administration. Spike-specific T cell responses were similar for frail and non-frail participants, regardless of administration route. Frail participants who received intradermal BNT162b2 had fewer local adverse events (AEs), but higher systemic AEs than non-frail participants.
Conclusion
Similar immune responses across vaccine routes warrants further evaluation of intradermal BNT162b2 in frail geriatric populations. Frail participants may be more sensitive to reporting systemic AEs.
Registration of clinical trials
The parent study was registered under the Thai Clinical Trials Registry (TCTR20220112002).
期刊介绍：
There is increasing scientific and clinical interest in the interactions of nutrition and health as part of the aging process. This interest is due to the important role that nutrition plays throughout the life span. This role affects the growth and development of the body during childhood, affects the risk of acute and chronic diseases, the maintenance of physiological processes and the biological process of aging. A major aim of "The Journal of Nutrition, Health & Aging" is to contribute to the improvement of knowledge regarding the relationships between nutrition and the aging process from birth to old age.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
